Smallpox vaccine PGD template

PGD template for administering smallpox vaccine in response to monkeypox.

Applies to England


Smallpox patient group direction (PGD) template

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email Please tell us what format you need. It will help us if you say what assistive technology you use.


This patient group direction (PGD) template supports the administration of the smallpox vaccine, modified vaccinia virus Ankara - Bavarian Nordic (MVA-BN), to individuals identified for immunisation in response to monkeypox.

The smallpox PGD v01.00 is valid from 2 August 2022 to 1 August 2023.

UKHSA smallpox v1.00 PGD – for information:

  • at present, there are no stocks of the UK licensed MVA-BN vaccine Imvanex® available
  • the Medicines and Healthcare products Regulatory Agency (MHRA) have granted batch-specific variation for batch FDP00012 to the US licensed vaccine Jynneos®, in view of the urgency of the need to manage the monkeypox outbreak – only this vaccine can be used under the UKHSA smallpox PGD

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should used with reference to current national recommendation on monkeypox vaccination, the Green Book and the Direct Healthcare Professional Communication letter from Bavarian Nordic the differences between Imvanex® brand (licensed in GB/UK) and Jynneos® brand (licensed in US) of live modified vaccinia virus Ankara.

Published 5 August 2022
Last updated 5 August 2022 + show all updates
  1. Corrected review date.

  2. First published.